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Purpose: The value of an immunochromatographic test for tuberculosis (ICT-TB) combined 
with clinical predictors has yet to be evaluated in Thailand. This study aimed to assess any 
additional diagnostic value of an ICT-TB test over that of clinical predictors in a group of human 
immunodeficiency virus (HIV) patients as well as in subgroups of HIV patients classified by 
clinical risk scores.
Patients and methods: An extended cross-sectional study was conducted at a community 
hospital in Chiang Rai and a general hospital in Lampang. HIV patients registered between 
April 2009 and May 2010 were screened by a locally made ICT-TB test, including 38, 16, and 
6 kD Microbacterium tuberculosis antigens, as well as by routine evaluations for TB diagnosis. 
Demographic data, medical history, signs, and symptoms were recorded. Participants were fol-
lowed up for 2 months for final ascertainment of TB diagnosis.
Results: Of 206 patients, 37 (18%) had TB. Four clinical predictors were identified: low body 
mass index (,19 kg/m2), prolonged cough (duration .2 weeks), shaking chills ($1 week), 
and no use of antiretrovirals. The area under the receiver operating curve was 90.2%; adding 
the ICT-TB test result increased the area nonsignificantly to 91.6% (P = 0.40). When patients 
were categorized by risk scores derived from selected clinical predictors into low (scores #7) 
and high (scores .7) TB risk groups, a positive ICT-TB test increased the positive predictive 
value nonsignificantly in the low risk group (from 12.5% to 27.3%, P = 0.17) and the high risk 
group (from 78.6% to 80.8%, P = 0.73).
Conclusion: In this study setting, the ICT-TB test did not enhance TB diagnosis over the four 
clinical predictors in the overall group or any subgroups of HIV patients classified by clinical 
risk scores.
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Introduction
Human immunodeficiency virus (HIV) and tuberculosis (TB) co-infection constitutes a 
high-burden disease in Thailand, where 12,890 individuals died from TB in 2009 and 
where HIV accounts for 17% of TB cases, the highest figure in the south-east Asian 
region.1 Early case identification followed by adequate treatment is the cornerstone 
of TB control programs. Thailand’s rank of 18th among 22 high-burden countries for 
TB is partly attributed to inadequate case evaluation and treatment default, which also 
result in increased deaths and contribute to underperformance on the World Health 
Organization (WHO) target for treatment success (81% versus 85%).1
Efforts to improve TB diagnosis by new technology have commonly faced 
the challenges of high equipment cost, lack of skilled technicians, and excessive 
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turnaround time.2 Rapid immunochromatographic test 
(ICT) technology may be the exception to this rule: when 
used as a serodiagnostic test for TB antibodies (ICT-TB), 
this technology is affordable, simple and safe to use, and 
produces results within 25 minutes.3 However, in an HIV-
infected population, several antigens may be recognized 
by the antibodies, thereby limiting the diagnostic valid-
ity of such tests.4 Previous studies have reported a wide 
range of sensitivity of ICT-TB tests in HIV patients (from 
0% to 80%); specificity was also very variable, ranging 
from 39% to 97.4%.4–8 A landmark study, conducted by 
the WHO Special Programme for Research and Training 
in Tropical Diseases in 2008, showed poor performance of 
19 commercial rapid diagnostic tests in HIV patients, with 
sensitivity reduced by an average of 22%–43% compared 
with that in HIV-negative patients.9 In Thai settings, only 
two diagnostic validity studies, on the use of lipoarabi-
nomannan and 38-kD recombinant antigens using pleural 
effusion and serum, have been reported.4,5
In an intensified effort to find cases of active TB in 
Thailand, a general screening tool, which disregards HIV 
status, is currently being used; this tool consists of simple 
questions relating to signs and symptoms of TB. From a 
recent review, the best predictors for TB diagnosis in HIV 
patients living in resource-constrained settings are pres-
ence of cough (for any duration), fever, night sweats, or 
weight loss.10 Other signs, symptoms, and simple labora-
tory tests proposed by other studies are fatigue,11,12 shaking 
chills,12 loss of appetite,12 difficulty in breathing,12 chest 
pain,12 abdominal pain,12 nausea/vomiting,12 body mass 
index (BMI),11,12 lymphadenopathy,11,12 hemoglobin level 
of ,10 g/dL,12 tuberculin skin test positivity,12 hospital-
ization upon registration,12 lack of antiretroviral (ARV) 
therapy,11,12 chest radiograph abnormalities,11,13,14 and 
CD4 cell count.11,14 However, the proposed combinations 
of predictors, as well as the performance of such predic-
tor combinations, varies between studies. The validity of 
such existing screening tools is unknown in the setting of 
Thailand; furthermore, the value of an ICT-TB test used in 
combination with clinical predictors has yet to be evaluated 
in Thailand.
Therefore, the objective of this study was to identify 
clinical characteristics, including demographics, signs, and 
symptoms that may be used to predict the presence of active 
TB, as well as to evaluate the diagnostic value of ICT-TB 
testing over such clinical predictors in subgroups of HIV 
patients stratified by clinical risk scores.
Materials and methods
study settings and population
The study protocol was approved by two institutional review 
boards: The Faculty of Medicine, Chiang Mai University and 
Lampang Regional Hospital.
All HIV patients aged 18 years or older seeking medical 
care or reporting for annual checkup at either a TB clinic 
or an ARV clinic between April 2009 and May 2010, 
regardless of TB signs and symptoms, were eligible for 
the study. Outpatient data, including clinical signs and 
symptoms, and blood samples were collected on the first 
day. Data from those admitted as inpatients were collected 
in the wards.
Study settings included Maesai District Hospital, a 
community hospital in Chiang Rai, and Lampang Hospital, 
a general hospital in Lampang, Thailand. Patients who were 
receiving TB treatment or isoniazid prophylaxis treatment 
(IPT) at the time of or within 1 year prior to recruitment 
were excluded.
Data collection
The attending physician or trained nursing staff interviewed 
participants and recorded data in a case record form. Data 
collected included patient demographics and clinical data, 
comprising medical history, history of TB diagnosis, history 
of TB contact, and ARV prescription. Data regarding duration 
of signs and symptoms were also collected; these included 
cough, cough with sputum, hemoptysis, fever, diarrhea, 
weight loss, night sweats, dyspnea, chest pain, nausea or 
vomiting, abdominal pain, loss of appetite, fatigue, shaking 
chills, and size of lymphadenopathy. Laboratory results at 
recruitment, such as abnormal chest radiograph, complete 
blood count, and CD4 cell count, were also collected.
index and reference tests
iCT-TB
As the index test, a locally produced ICT-TB test containing 
a membrane strip pre-coated with colloid gold-  conjugated 
recombinant Microbacterium tuberculosis antigens 
(38, 16, and 6 kD) was used. In this test, the patient’s 
sample migrates chromatographically along the membrane 
to the test region, where a visible line forms if an antigen-
antibody-antigen-gold particle complex forms (positive 
result). The absence of a visible color band within the test 
window indicates a negative result. The test was interpreted 
as invalid if the reference and the control bands did not 
appear.15Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Blood serum specimens, approximately 100 µL, were 
obtained on the day of recruitment by research staff who had 
received training in the implementation of the ICT-TB test. All 
patients were tested with the ICT-TB on the day of enrolment 
or not later than 3 days after enrolment. Results were inter-
preted within 20 minutes by three interpreters blinded to each 
other’s findings and to the patient’s clinical information. When 
at least two readers indicated a positive result, the result was 
recorded as “positive.” Indeterminate results were excluded 
from the analysis of the ICT-TB test performance.
reference tests
Criteria for a definitive TB diagnosis were defined as smear 
positivity, positive culture of sputum or other specimens, 
positive clinical and radiological evaluation, response to TB 
treatment, or histological characteristics indicative of TB in 
biopsy specimens, as is the standard clinical practice. Only 
for registered TB cases, sputum or other specimens were sent 
for M. tuberculosis culture. All patients were followed up for 
2 months to ascertain TB diagnosis.
statistical analysis
Predictors of TB were selected using a two-stage procedure. 
First, predictors with a P-value of ,0.05 were selected 
by univariate logistic regression. Second, using multi-
variate logistic regression with a forward method of model 
selection,16 predictors of TB in the final model were selected 
not only from statistical significance but also from clinical 
significance. Missing predictor values were dealt with using 
a multiple imputation method.
Models with/without the ICT-TB test were compared 
by adding the ICT-TB test results into the clinical predictor 
model. To assess whether the model prediction was improved 
by the ICT-TB, two methods were used: the area under 
receiver operating characteristic curve (AuROC) method, 
and the net reclassification improvement (NRI) method.17 
Models with and without ICT-TB were validated and assigned 
classical diagnostic values.
For the scoring scheme, each variable from the final 
model was weighted by its coefficient and transformed to an 
item score. The cutoff points of total scores, determined by 
statistical significance and the yield of prediction, were used 
to classify HIV patients into the low- or high-risk groups. 
The positive predictive value (PPV) of the ICT-TB test for 
each category was compared with the prior probability 
(prevalence) by the Fisher’s exact probability test. Statistical 
significance level was set at 0.05 for type I error.
The number of patients required in the study was esti-
mated based on previous information of an odds ratio of 
9.6 and 16.9% prevalence in the non-TB group.15 Thus, to 
achieve 90% power and a significant finding at alpha = 0.05, 
18 active TB patients were required. Given the prevalence 
of active TB (17%) in the study population,18 106 HIV 
patients were needed; in order to compensate for 20% miss-
ing data, the final minimum number of HIV patients needed 
was 128.
Results
Of 213 HIV patients eligible for the study, seven (3.3%) 
were excluded because of ongoing TB and IPT treat-
ment at the time of enrolment. The final analysis included 
206 HIV patients, all of whom underwent the ICT-TB tests. 
Of these, 37 (18%) were diagnosed with active TB, includ-
ing 33 (94.3%) with pulmonary TB and four (5.7%) with 
extrapulmonary TB cases (Figure 1).
Using univariate logistic regression, the following patient 
characteristics, signs, and symptoms were significant: BMI, 
history of contact, CD4 count level, ARV prescribed, cough, 
fever, weight loss, dyspnea, chest pain, loss of appetite, 
fatigue, and shaking chills (Tables 1 and 2).
The predictors that remained in the final model were 
cough, shaking chills, BMI, and ARV prescribed, with CD4 
clustered in the model (Table 3). Although those with a posi-
tive ICT-TB test result were 5.05 times more likely to have 
active TB (95% confidence interval, 0.66–38.48) compared 
with those who tested negative, the ICT-TB test itself did not 
add any statistical significance to the final model (Table 3).
These predictors explained 90.2% of the probability 
(AuROC) of active TB. When the ICT-TB test result was 
added in the model, it increased the probability of active 
TB to 91.6%; this increase was not statistically significant 
(P = 0.40) (Figure 2). This nonimprovement of the model by 
the ICT-TB test result was also confirmed by the NRI analysis 
(P = 0.51). Adding the ICT-TB test result did not enhance 
any of the diagnostic values in the validation of the model 
(without ICT-TB versus with ICT-TB): sensitivity, 48.0% 
versus 52.0%; specificity, 95.3% versus 94.7%; PPV , 63.2% 
versus 61.9%; and NPV , 91.7% versus 92.2%. Both models 
had equal values for correct classification (88.6%).
This study further investigated whether the ICT-TB 
would enhance the diagnosis in subgroups of individuals 
with low versus high risk of having TB. The subgroups were 
categorized by a risk score system developed from each 
selected predictor, weighted by the coefficient from the final Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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HIV patients with/without 13 clinical predictors (n = 213):
BMI, ARV received, history of contact, CD4 level, hemoglobin level, cough,
fever, weight loss, dyspnea, chest pain, loss of appetite, fatigue, shaking chills
Missing values:
-CD4 level 25 (12.1%)
-BMI 6 (2.9%)
Excluded patients (n = 7)
-On TB treatment (n = 4)
-On IPT treatment (n = 3)
ICT-TB (n = 206)
Positive result (n = 18) Negative result (n = 188) Inconclusive result (n = 0)
Reference standard (n= 18)
No reference
standard (n = 0)
Reference standard (n = 188)
No reference
standard (n = 0)
With TB
(n = 11)
End of two mo. of  F/U
Change diagnosis to
without TB (n = 2)
Without TB
(n = 7)
Without TB (n = 7 + 2)
With TB
(n = 30)
End of two mo. of F/U
Change diagnosis 
to without TB (n = 2)
Without TB
(n = 158)
Without TB (n = 158+2)
With TB (n = 9)
-ETB: 1 pt.
-PTB: 8 pts.
-Asthma:1 pt.
-Bronchitis: 6 pts.
-Lung cancer: 1 pt.
-Absence of chest disease:
 1 pt. With TB (n = 28)
-ETB: 3 pts.
-PTB: 25 pts.
-Bronchitis: 10 pts.
-FOU: 1 pt.
-Lung cancer: 1 pt.
-PCP: 6 pts.
-Penicilliosis: 1 pt.
-Pneumonia: 5 pts.
-Absence of chest disease: 137 pts.
Figure 1 study flow diagram for TB diagnosis by clinical predictors combined with ICT-TB in HIV patients. 
Abbreviations: ARV, antiretroviral; BMI, body mass index; ETB, extrapulmonary TB; FOU, fever of unknown origin; F/U, follow-up; HIV, human immunodeficiency virus; 
iCT-TB, immunochromatographic test for tuberculosis; iPT, isoniazid prophylaxis treatment; mo, months; PCP, Pneumocystis carinii pneumonia; pt, patient; PTB, pulmonary 
TB; TB, tuberculosis.
Table 1 Characteristics of hiV patients with (n = 37) or without TB (n = 169)
Characteristics With TB Without TB Crude OR 
(95% CI)
P-value
Male 18 (48.6) 82 (48.5) 1.00 (0.49–2.03) 0.989
Age, years
  Mean ± sD
 
38.4 ± 12.1
 
39.9 ± 9.6
 
0.99 (0.95–1.02)
 
0.414
BMi, kg/m2
  ,19 20 (58.8) 42 (25.6) 4.15 (1.92–8.94) ,0.001
ArVs not prescribed 28 (75.7) 27 (16.0) 16.36 (6.95–38.52) ,0.001
history of Oi 4 (10.8) 38 (22.5) 0.42 (0.14–1.25) 0.120
history of TB diagnosis 6 (16.2) 17 (10.1) 1.73 (0.63–4.47) 0.286
history of TB contact 5 (13.5) 5 (3.0) 5.12 (1.40–18.73) 0.013
CD4 cell count, cells/µL
  ,200 19 (70.4) 33 (21.4) 8.71 (3.50–21.66) ,0.001
hemoglobin, g/dL
 , 10 15 (46.9) 18 (11.3) 6.96 (2.98–16.286) ,0.001
WBC count, 1000/dL
  Median (range) 7.3 (1–23.2) 6.0 (1–24) 1.10 (0.99–1.23) 0.064
hematocrit, %
  Median (range) 31.8 (13.7–45.7) 37.7 (8.5–49.9) 0.88 (0.82–0.94) ,0.001
Platelet count, 1000/mL
  Median (range) 298.0 (69–612) 317.0 (28–912) 1.00 (0.99–1.00) 0.774
Notes: Numbers are n (%), mean ± sD, or median (range).
Abbreviations: BMI, body mass index; CI, confidence interval; HIV, human immunodeficiency virus; OI, opportunistic infection; OR, odds ratio; SD, standard deviation; 
TB, tuberculosis; WBC, white blood cell.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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When HIV patients were classified into low TB risk 
(scores #7) and high TB risk (scores .7) groups, the PPV 
of ICT-TB test (post-test probability) increased insignificantly 
from prevalence (pre-test probability) in both the low risk 
Table 2 signs and symptoms of hiV patients with (n = 37) or without TB (n = 169)
Signs and symptoms With TB Without TB Crude OR 
(95% CI)
P-value
Cough
 # 2 weeks 20 (54.1) 159 (94.1) 1.0
 . 2 weeks 17 (45.9) 10 (5.9) 13.52 (5.44–33.54) ,0.001
Cough with sputum
 # 2 weeks 25 (67.6) 164 (97.0) 1.0
 . 2 weeks 12 (32.4) 5 (3.0) 15.74 (5.11–48.49) ,0.001
hemoptysis
 # 1 week 35 (94.6) 168 (99.4) 1.0
 . 1 week 2 (5.4) 1 (0.6) 9.49 (0.84–107.53) 0.069
Fever
 , 1 week 30 (81.1) 156 (92.3) 1.0
 $ 1 week 7 (18.9) 13 (7.7) 2.80 (1.03–6.00) 0.043
Diarrhea
 , 1 week 35 (94.6) 167 (98.8) 1.0
 $ 1 week 2 (5.4) 2 (1.2) 4.77 (0.65–35.03) 0.124
Weight loss
 # 1 week 19 (52.8) 150 (89.8) 1.0
  1–2 weeks 4 (11.1) 4 (2.4) 7.60 (1.76–32.80) 0.007
 $ 2 weeks 13 (36.1) 13 (7.8) 7.60 (3.09–18.68) ,0.001
Night sweats
 , 1 week 34 (91.9) 162 (96.4) 1.0
 $ 1 week 3 (8.1) 6 (3.6) 2.40 (0.57–10.06) 0.232
Dyspnea
 # 1 week 30 (81.1) 159 (94.1) 1.0
 . 1 week 7 (18.9) 10 (5.9) 3.71 (1.31–10.51) 0.014
Chest pain
 # 1 week 25 (67.6) 159 (94.1) 1.0
 . 1 week 12 (32.4) 10 (5.9) 7.63 (2.98–19.52) ,0.001
Nausea/vomiting
 # 1 week 36 (97.3) 168 (99.4) 1.0
 . 1 week 1 (2.7) 1 (0.6) 4.67 (0.29–76.36) 0.280
Abdominal pain
 # 2 weeks 36 (97.3) 166 (98.2) 1.0
 . 2 weeks 1 (2.7) 3 (1.8) 1.19 (0.13–11.00) 0.877
Loss of appetite
 # 1 week 29 (78.4) 155 (91.7) 1.0
 . 1 week 8 (21.6) 14 (8.3) 3.05 (1.18–7.94) 0.022
Fatigue
 # 1 week 25 (67.6) 153 (91.1) 1.0
 . 1 week 12 (32.4) 15 (8.9) 4.93 (2.07–11.75) ,0.001
shaking chills
 , 1 week 31 (83.8) 164 (97.0) 1.0
 $ 1 week 6 (16.2) 5 (3.0) 6.35 (1.82–22.10) ,0.001
Lymphadenopathy
  No 35 (94.6) 169 (100.0) – 0.032a
  Yes 2 (5.4) 0 (0.0) NA
Notes: Numbers are n (%); aFisher’s exact test.
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; NA, not applicable; OR, odds ratio; TB, tuberculosis.
model, and transformed by dividing the value by the smallest 
coefficient (1.5 for cough and BMI). The value derived was 
rounded up to the nearest whole number to assign a final 
score; scores ranged from 0 to 11 (Table 4).Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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  demonstrated from ROC area curves, increased from 90.2% 
to 91.6%. NRI additionally confirmed the nonsignificant ben-
efit of the ICT-TB test. Furthermore, we externally validated 
the best performing rule for TB diagnosis in HIV patients 
recommended by WHO, ie, presence of cough for any dura-
tion, fever, night sweats, or weight loss, in our dataset.10 The 
result was in accordance with the present authors’ findings. 
AuROC without the ICT-TB was 85.5%, compared with 
86.3% with inclusion of the ICT-TB test result; this increase 
was not statistically significant (P = 0.19). Subgroup analysis 
was performed to assess any added diagnostic value in low 
and high TB risk groups, stratified by a clinical risk score; 
post-test probability of the ICT-TB did not increase signifi-
cantly from pre-test probability in either subgroup, confirm-
ing a “nonbenefit” of the ICT-TB test over the screening tool 
in HIV patients.
The ICT-TB test used for the study is one among several 
commercial kits available in this country. Because antibody 
responses to M. tuberculosis antigens may be heterogeneous 
for a number of reasons, multiple antigens were used in the 
ICT-TB test to increase the performance of the test.15 The 
added diagnostic value may vary with the use of ICT-TB tests 
containing different antigens. However, the authors of this 
paper considered that the ICT-TB test selected for use in this 
study should perform best since it is a locally produced test 
using antigens derived from an endogenous M. tuberculosis 
strain and had shown higher diagnostic accuracy than an 
imported test.20
The combination of factors best predicting active TB 
in HIV patients was as follows: BMI, ,19 kg/m2; cough 
for .2 weeks; shaking chills for $1 week; and lack of ARV 
prescription. This is also partly consistent with   predictors 
Table 4 Logistic coefficients, transformed scores, and assigned 
item scores of significant clinical predictors
Clinical  
predictors
Coefficient Transformed  
score
Assigned 
score
Cough
  #2 weeks 0 0 0
  .2 weeks 1.5 1 2
shaking chills
  ,1 week 0 0 0
  $1 week 2.4 1.6 3
ArVs prescribed
  Yes 0 0 0
  No 2.9 1.9 4
BMi (kg/m2)
  $19 0 0 0
  ,19 1.5 1 2
Abbreviations: ArV, antiretroviral; BMi, body mass index.
Table 3 Multivariable OR of significant clinical predictors and 
AurOC and 95% Ci, without or with iCT-TB test added to the 
model
Clinical  
predictors
Multivariable ORa (95% CI)
Without ICT-TB test With ICT-TB test
Cough
   .2 weeks versus  
#2 weeks
4.48 (4.25–4.72) 3.51 (2.74–4.50)
shaking chills
   $1 week versus  
,1 week
11.09 (9.49–12.95) 13.13 (7.97–21.62)
ArVs prescribed
  No versus yes 18.91 (1.41–253.58) 20.62 (1.30–328.07)
BMi, kg/m2
  ,19 versus $19 4.59 (4.39–4.81) 4.97 (3.87–6.37)
iCT-TB test
    Positive versus 
negative
– 5.05 (0.66–38.48)
AurOC (95% Ci) 0.90 (0.85–0.95) 0.92 (0.88–0.95)
Note: aAdjusted for CD4 cell count by logistic regression clustering.
Abbreviations: ArV, antiretroviral; AurOC, area under receiver operating curve; 
BMI, body mass index; CI, confidence interval; ICT-TB, immunochromatographic 
test for tuberculosis; Or odds ratio.
0
.
7
5
1
.
0
0
0
.
5
0
T
r
u
e
 
p
o
s
i
t
i
v
e
0
.
0
0
0
.
2
5
Clinical predictors plus ICT-TB test (AuROC = 91.6)
Clinical predictors only (AuROC = 90.2)
0.00
False positive
1.00 0.75 0.50 0.25
Figure 2 AurOC of four clinical predictors, with (solid line) or without (dashed 
line) additional iCT-TB test. 
Abbreviations:  AurOC,  area  under  receiver  operating  curve;  iCT-TB, 
immunochromatographic test for tuberculosis.
(from 12.5% to 27.3%, P = 0.17) and high risk groups (from 
78.6% to 80.8%, P = 0.73) (Table 5).
Discussion
In January 2011, WHO reported the lack of accuracy of 
serological tests for TB in HIV populations;19 however, the 
present study is the first to assess whether addition of the 
ICT-TB test result extends the diagnostic value of a screening 
tool based on clinical predictors in Thailand. No statistically 
significant additional value over the four clinical factors 
selected was found, although the prediction probability, Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
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from other studies, ie, BMI of #18 kg/m2,12 and cough 
for .2 weeks.12 Other predictors found associated with 
active TB in other studies, but not in the present study, were 
weight loss,10 night sweats,10 fever,10 lymphadenopathy,11,12 
and general weakness;11,12 these discrepant results are likely 
due to population differences. In some previous studies, an 
abnormal chest radiograph was used as one of the predictors 
and was proven to increase sensitivity in detection of active 
TB.10,13,14 However, in this study, abnormal chest radiograph 
was excluded as a predictor because it was used as one of 
the criteria for TB definition, which was likely to introduce 
incorporation bias.
From an economic perspective, using the ICT-TB may not 
seem to be particularly burdensome due to its low cost (less 
than US$5). However, given the nonbenefit of the test, the 
Thai Ministry of Public Health budget may save more than 
US$8,000–10,000 per year by solely following the screening 
tool developed in this study; these funds could be reallocated 
to subsidize other HIV-related care programs, such as TB 
prevention in the population at large.
Study limitations are as follows. First, M. tuberculosis 
culture was not used as a gold standard for diagnosis due 
to limited accessibility in many areas. In the present study, 
14 (37.8%) of 37 TB cases sent for M. tuberculosis culture 
yielded a result; of these, 13 (92.9%) were culture-positive, 
reflecting a high consistence with the reference standard 
used in the study. Given the small number of cases with 
culture results, M. tuberculosis culture could not be used as 
a reference in regression analysis. A second limitation may 
be the generalizability of the study, which may be limited 
due to the variability of the predicting factors, prevalence 
of TB severity, and spectrum of the target population. 
Therefore, validation of the model is required before it can 
be adopted as routine in other health care settings. Third, 
some variables had missing values, such as CD4 cell counts 
(12.1%) and BMI (2.9%). Results of multiple imputation 
analysis showed the same tendency, with slightly different 
effect sizes for each predictor. In both the original analysis 
and that using multiple imputation data, the ICT-TB test did 
not significantly add to the clinical predictors (P = 0.07). 
During model fitting, CD4 levels were found statistically 
significant only in univariate analysis; however, given its 
clinical significance, this variable was taken into account by 
clustering in the final model. In future research, subgroup 
analysis of CD4 cell count level should be considered. Most 
HIV/TB patients with CD4 cell counts less than 200 cells/µL 
have low immunity and can be diagnosed with TB by rou-
tine clinical predictors (without the ICT-TB); therefore, 
this group may be prone to selection bias. Additionally, in 
a previous study, the ICT-TB test performed better when 
the CD4 cell count was more than 200 cells/µL.5 Lastly, the 
relatively small number of active TB patients in this study 
may limit the power of analysis for some variables; future 
research with a larger sample is warranted to confirm the 
results of the present study.
However, given that the present study is prospective in 
nature and patients were followed up for 2 months, mis-
classification of TB diagnosis should be minimal; this is a 
strength of the study.
Conclusion
In this study setting, the ICT-TB test did not improve TB 
diagnosis compared with the 4 clinical predictors in the 
overall group and any subgroups of HIV patients, as classified 
by clinical risk scores. Further research will be necessary to 
apply and compare the diagnostic performance of the clini-
cal algorithm suggested by WHO with the clinical predictors 
used in this study.
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Table 5   Distribution  of  hiV  patients  with  (n  =  34)  or  without  TB  (n  =  164)  in  each  risk  category,  PPV  of  iCT-TB  test   
and 95% Ci
Risk category (score) With TB 
n (%)
Without TB 
n (%)
Prior probability (prevalence)  
(95% CI)
PPV (95% CI) 
of ICT-TB
Low risk (#7) 23 (12.5) 161 (87.5) 12.5 (8.1–18.2) 27.3 (6.0–61.0)
high risk (.7) 11 (78.6) 3 (21.4) 78.6 (4.9–95.3) 80.8 (28.4–99.5)
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; ICT-TB, immunochromatographic test for tuberculosis; PPV, positive predictive value; 
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